Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bone loss in prostate cancer
NCT00925600Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2009
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of denosumab in low bone mineral density, osteopenia, osteoporosis, sponsored by Amgen. Started Nov 2009; status: completed.
02
Drugs
denosumab
03
Conditions
low bone mineral densityosteopeniaosteoporosis
Beyond the preview
Go deeper on NCT00925600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00925600.